SEHK:2228Life Sciences
Stanford Drug Discovery Deal Could Shape The Case For XtalPi Holdings Stock
On 17 September 2026, XtalPi Holdings announced that subsidiary LCC Technologies entered a drug discovery collaboration with Stanford University, pairing Stanford’s disease biology research with LCC’s AI-driven PACE platform for small molecule development across multiple disease areas.
The agreement creates a joint steering committee that screens Stanford investigators’ proposals and directs LCC’s automated discovery resources toward the projects with the strongest scientific rationale and...